IEX Stock Analysis: IDEX | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 17.232m USD | 12M Return: 43.3% | US45167R1041 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 150M
EPS Trend: 0.4%
Qual. Beats: 6
Rev. Trend: 83.9%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IDEX Corporation (NYSE: IEX) is a diversified industrial manufacturer headquartered in Northbrook, Illinois, operating through three reportable segments: Health & Science Technologies (HST), Fluid & Metering Technologies (FMT), and Fire & Safety/Diversified Products (FSDP). Its product portfolio spans precision fluidics, pumps, valves, flow meters, sealing solutions, laboratory and medical components, optical technologies, firefighting and rescue equipment, and precision dispensing systems for paints and colorants. The company serves customers across the United States, North America, Europe, Asia, and other international markets, and was incorporated in 1987.
The company operates a decentralized, niche specialty manufacturing model, acquiring and operating businesses that hold leading positions in focused industrial, life sciences, and safety end markets. Classified within the Industrials sector under Industrial Machinery & Components, IDEX employs a multi-platform structure designed to leverage shared engineering and operational capabilities across highly fragmented sub-markets, allowing it to serve specialized customer needs across fluid handling, life sciences, and safety equipment.
- HST segment revenue grows on biopharma and semiconductor demand
- FMT margins face pressure from industrial production slowdown
- Serial acquisitions expand portfolio across health and fluid markets
| Net Income: 519.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.72 > 1.0 |
| NWC/Revenue: 33.24% < 20% (prev 32.53%; Δ 0.71% < -1%) |
| CFO/TA 0.10 > 3% & CFO 716.7m > Net Income 519.5m |
| Net Debt (1.29b) to EBITDA (956.8m): 1.35 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.2m) vs 12m ago -1.98% < -2% |
| Gross Margin: 44.70% > 18% (prev 43.40%; Δ 1.30% > 0.5%) |
| Asset Turnover: 51.94% > 50% (prev 48.59%; Δ 3.35% > 0%) |
| Interest Coverage Ratio: 11.66 > 6 (EBIT TTM 744.1m / Interest Expense TTM 63.8m) |
| A: 0.17 (Total Current Assets 1.77b - Total Current Liabilities 581.6m) / Total Assets 6.93b |
| B: 0.67 (Retained Earnings 4.66b / Total Assets 6.93b) |
| C: 0.11 (EBIT TTM 744.1m / Avg Total Assets 6.90b) |
| D: 1.37 (Book Value of Equity 4.01b / Total Liabilities 2.92b) |
| Altman-Z'' = 5.48 = AAA |
| DSRI: 1.07 (Receivables 547.8m/476.1m, Revenue 3.59b/3.34b) |
| GMI: 0.97 (GM 43.40% / 44.70%) |
| AQI: 0.97 (AQ_t 0.68 / AQ_t-1 0.70) |
| SGI: 1.07 (Revenue 3.59b / 3.34b) |
| TATA: -0.03 (NI 519.5m - CFO 716.7m) / TA 6.93b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of August 24, 2026, the stock is trading at USD 234.39 with a total of 478,908 shares traded. Over the past week, the price has changed by -1.90%, over one month by +5.48%, over three months by +11.38% and over the past year by +43.32%.
Current recommended Stop Loss: 225.20 (which is 3.9% or 1.7 ATR below the current price).
IDEX has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy IEX.
- StrongBuy: 6
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 254.5 | 8.6% |
P/E Trailing = 33.7789
P/E Forward = 26.8097
P/S = 4.8063
P/B = 4.3123
P/EG = 1.9139
Revenue TTM = 3.59b USD
EBIT TTM = 744.1m USD
EBITDA TTM = 956.8m USD
Long Term Debt = 1.86b USD (from longTermDebt, last quarter)
Short Term Debt = 27.0m USD (from shortTermDebt, last quarter)
Debt = 1.91b USD (from shortLongTermDebtTotal, last quarter) + Leases 26.6m
Net Debt = 1.29b USD (calculated: Debt 1.91b - CCE 621.3m)
Enterprise Value = 18.5b USD (17.2b + Debt 1.91b - CCE 621.3m)
Interest Coverage Ratio = 11.66 (Ebit TTM 744.1m / Interest Expense TTM 63.8m)
EV/FCF = 28.87x (Enterprise Value 18.5b / FCF TTM 641.5m)
FCF Yield = 3.46% (FCF TTM 641.5m / Enterprise Value 18.5b)
FCF Margin = 17.89% (FCF TTM 641.5m / Revenue TTM 3.59b)
Net Margin = 14.49% (Net Income TTM 519.5m / Revenue TTM 3.59b)
Gross Margin = 44.70% ((Revenue TTM 3.59b - Cost of Revenue TTM 1.98b) / Revenue TTM)
Gross Margin QoQ = 46.36% (prev 44.89%)
Tobins Q-Ratio = 2.67 (Enterprise Value 18.5b / Total Assets 6.93b)
Interest Expense / Debt = 3.34% (Interest Expense 63.8m / Debt 1.91b)
Taxrate = 23.78% (162.0m / 681.3m)
NOPAT = 567.2m (EBIT 744.1m * (1 - 23.78%))
Current Ratio = 3.05 (Total Current Assets 1.77b / Total Current Liabilities 581.6m)
Debt / Equity = 0.48 (Debt 1.91b / totalStockholderEquity, last quarter 4.01b)
Debt / EBITDA = 1.35 (Net Debt 1.29b / EBITDA 956.8m)
Debt / FCF = 2.01 (Net Debt 1.29b / FCF TTM 641.5m)
Total Stockholder Equity = 4.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.53% (Net Income 519.5m / Total Assets 6.93b)
RoE = 12.91% (Net Income TTM 519.5m / Total Stockholder Equity 4.02b)
RoCE = 12.65% (EBIT 744.1m / Capital Employed (Equity 4.02b + L.T.Debt 1.86b))
RoIC = 9.15% (NOPAT 567.2m / Invested Capital 6.20b)
WACC = 8.71% (E(17.2b)/V(19.1b) * Re(9.39%) + D(1.91b)/V(19.1b) * Rd(3.34%) * (1-Tc(0.24)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.29 | Cagr: -1.00%
[DCF] Terminal Value 75.38% ; FCFF base≈619.7m ; Y1≈670.0m ; Y5≈823.0m
[DCF] Fair Price = 143.6 (EV 11.9b - Net Debt 1.29b = Equity 10.6b / Shares 73.7m; r=8.71% [WACC]; 5y FCF grow 9.28% → 2.50% )
EPS Correlation: 0.36 | EPS CAGR: 0.01% | SUE: 3.06 | # QB: 6
Revenue Correlation: 83.90 | Revenue CAGR: 3.66% | SUE: 0.87 | # QB: 4
EPS current Quarter (2026-09-30): EPS=2.23 | Chg30d=+1.89% | Revisions=+55% | Analysts=10
EPS current Year (2026-12-31): EPS=8.82 | Chg30d=+3.85% | Revisions=+79% | GrowthEPS=+11.0% | GrowthRev=+6.8%
EPS next Year (2027-12-31): EPS=9.58 | Chg30d=+3.81% | Revisions=+80% | GrowthEPS=+8.6% | GrowthRev=+5.7%
[Analyst] Revisions Ratio: +85% (up=30, down=1)